News – Page 939 – Endpoints News

Still trailing far behind a blockbuster rival, Novartis gathers another round of positive survival data for Kisqali

6 years ago

Arie Belldegrun and the crew at Vida reap a $600M harvest for fund II — and they've got LA in their sights

6 years ago

Atlantic Healthcare's drug fails late-stage test; Translate Bio breaks out early CF data

6 years ago

FDA chief backs 2 new pathways to spur drug importation — but analysts shrug it all off

6 years ago

Merck's Keytruda makes the cut as a second-line monotherapy for certain esophageal cancer patients

6 years ago

Gilead chief Daniel O’Day isn’t done making headlines — with more R&D deals and lots of new hires to come

6 years ago

Amarin boosted as another milestone to the FDA’s big Vascepa decision flies by with no sign of an AdCom

6 years ago

Novartis' $18.5B in M&A under Vas Narasimhan says a lot about their careful — but opportunistic — deal strategy

6 years ago

Pedal to the metal, Amgen finally has a hot new drug star on its hands — and they have some news

6 years ago

Bayer, Orion win speedy approval for prostate cancer drug darolutamide

6 years ago

Wellington Partners tanks up with $237M for its next life sci fund — same strategy, but with more cash on hand

6 years ago

Approval in sight, Perceptive, OrbiMed double down on Foamix's antibiotic foam to the tune of $64M

6 years ago

Gates backs development work on a long-acting contraceptive pill

6 years ago

Founding NewLink CEO Charles Link is out; Chi-Med lines up two more drug filings

6 years ago

Eli Lilly axes an early-stage PD-L1/TIM-3 bispecific program in latest pipeline cleanup

6 years ago

The patent play: Biogen gets a PhIII boost for its bit-better take on the blockbuster MS franchise drug Tecfidera

6 years ago

Do you want to see what winning big in the R&D race looks like in the Big Pharma league?

6 years ago

FTC investigates J&J contracts regarding the drugmaker's blockbuster Remicade

6 years ago

Verastem taps board director and Eli Lilly vet Brian Stuglik to right the commercial boat

6 years ago

What is Pfizer going to buy next? Albert Bourla outlines his M&A strategy in the post-Upjohn era

6 years ago

Novartis’ Zolgensma joins growing list of medicines to lose accelerated assessment status in EU

6 years ago

Strapped for cash, Woodford's unraveling continues as listed fund considers kicking him out as manager

6 years ago

Genfit's elafibranor wins orphan status for primary biliary cholangitis; Cidara stock soars on positive anti-fungal ...

6 years ago

After painting a poor safety profile, Pfizer and Eli Lilly are shooting for a new pain drug OK anyway

6 years ago

First page Previous page 936 937 938939940 941 942 Next page Last page